<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426021</url>
  </required_header>
  <id_info>
    <org_study_id>MLN1202/CPH-001</org_study_id>
    <secondary_id>U1111-1169-0038</secondary_id>
    <secondary_id>JapicCTI-152874</secondary_id>
    <nct_id>NCT02426021</nct_id>
  </id_info>
  <brief_title>Phase 1 Single Subcutaneous Dose Study of MLN1202</brief_title>
  <official_title>A Phase 1, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of MLN1202 in the Japanese and Caucasian Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate the safety, pharmacokinetics, and&#xD;
      pharmacodynamic effect of a single dose of MLN1202 in healthy Japanese male adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single dose, phase 1 study in healthy Japanese and Caucasian male adults.&#xD;
&#xD;
      Japanese subjects will be assigned to Cohort J1 (at a dose of 75 mg), Cohort J2 (105 mg),&#xD;
      Cohort J3 (150 mg), or Cohort J4 (450 mg) in a randomized, double-blind, placebo-controlled&#xD;
      manner, while Caucasian subjects to Cohort C1 (at a dose of 75 mg) or Cohort C2 (150 mg) in&#xD;
      an open-label manner.&#xD;
&#xD;
      Takeda has made a business decision to terminate this study due to portfolio&#xD;
      re-prioritization. There were no safety or efficacy concerns.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business decision; No Safety or Efficacy Concerns&#xD;
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events</measure>
    <time_frame>Up to Day 37</time_frame>
    <description>The adverse event is defined as any unfavorable and unintended sign, symptom, or disease that develops when a drug is administered, irrespective of the causal relationship to the drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of MLN1202</measure>
    <time_frame>Up to Day 37</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) of MLN1202 in serum</measure>
    <time_frame>Up to Day 37</time_frame>
    <description>Area under the serum concentration-time curve during a dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum monocyte chemoattractant protein-1 (MCP-1) concentrations</measure>
    <time_frame>Up to Day 37</time_frame>
    <description>Serum MCP-1 concentrations will be measured at each protocol-specified time point, when blood samples are collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in monocyte count from baseline</measure>
    <time_frame>Up to Day 37</time_frame>
    <description>The absolute monocyte count will be determined at each protocol-specified time point, when blood samples are collected.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Japanese and Caucasian Male Adults</condition>
  <arm_group>
    <arm_group_label>Cohort J1: MLN1202 (75 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of MLN1202 (75 mg) in 6 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J1: placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of placebo in 2 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J2:MLN1202 (105 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of MLN1202 (105 mg) in 6 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J2: placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of placebo in 2 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J3: MLN1202 (150 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of MLN1202 (150 mg) in 6 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J3: placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of placebo in 2 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J4: MLN1202 (450 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of MLN1202 (450 mg) in 6 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J4: placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of placebo in 2 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C1: MLN1202 (75 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of MLN1202 (75 mg) in healthy Causacian male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C2: MLN1202 (150 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of MLN1202 (150 mg) in healthy Causacian male adults</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN1202</intervention_name>
    <description>Subcutaneous administration of MLN1202</description>
    <arm_group_label>Cohort C1: MLN1202 (75 mg)</arm_group_label>
    <arm_group_label>Cohort C2: MLN1202 (150 mg)</arm_group_label>
    <arm_group_label>Cohort J1: MLN1202 (75 mg)</arm_group_label>
    <arm_group_label>Cohort J2:MLN1202 (105 mg)</arm_group_label>
    <arm_group_label>Cohort J3: MLN1202 (150 mg)</arm_group_label>
    <arm_group_label>Cohort J4: MLN1202 (450 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN1202 Placebo</intervention_name>
    <description>Subcutaneous administration of MLN1202 placebo</description>
    <arm_group_label>Cohort J1: placebo</arm_group_label>
    <arm_group_label>Cohort J2: placebo</arm_group_label>
    <arm_group_label>Cohort J3: placebo</arm_group_label>
    <arm_group_label>Cohort J4: placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. In the opinion of the investigator, the participant is capable of understanding and&#xD;
             complying with protocol requirements.&#xD;
&#xD;
          2. The participant signs and dates a written informed consent form (ICF) prior to the&#xD;
             initiation of any study procedures.&#xD;
&#xD;
          3. The participant is a healthy adult man who is defined as Japanese (all parents and&#xD;
             grandparents of the participant are Japanese) or Caucasian (all parents and&#xD;
             grandparents of the participant are Caucasian).&#xD;
&#xD;
          4. The participant is between 20 and 45 years of age at the time of informed consent.&#xD;
&#xD;
          5. The participant has a body weight of at least 50 kg and has a body mass index (BMI)&#xD;
             between 18.5 and 25.0 kg /m2 when the participant is Japanese or between 18.5 and 30.0&#xD;
             kg /m2 when the participant is Caucasian at the time of screening and baseline&#xD;
             examination.&#xD;
&#xD;
          6. A male participant who is sexually active with a female partner of childbearing&#xD;
             potential and who has not received contraceptive therapy agrees to use adequate&#xD;
             contraception from the time of informed consent until 12 weeks (84 days) after&#xD;
             administration of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The participant has received any other investigational compound within 16 weeks (112&#xD;
             days) prior to administration of the study drug.&#xD;
&#xD;
          2. The participant has previously received agents containing MLN1202, a monoclonal&#xD;
             antibody or monoclonal antibody fragment.&#xD;
&#xD;
          3. The participant has been vaccinated within 4 weeks (28 days) prior to administration&#xD;
             of the study drug or is planning to be vaccinated during the study period.&#xD;
&#xD;
          4. The participant is a study site employee or immediate family member of the employee,&#xD;
             or may consent under duress.&#xD;
&#xD;
          5. The participant has poorly-controlled, clinically significant neurologic,&#xD;
             cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, or&#xD;
             endocrine disease, hemorrhagic disorder or other abnormalities which may impact the&#xD;
             ability of the participant to participate or potentially confound the study results.&#xD;
&#xD;
          6. The participant has recurrent serious or poorly-controlled infection and is considered&#xD;
             to have difficulty participating in the study by the investigator.&#xD;
&#xD;
          7. The participant has a history of hypersensitivity or allergies to MLN1202 or additives&#xD;
             contained in MLN1202 preparations.&#xD;
&#xD;
          8. The participant has a history of hypersensitivity or allergies to monoclonal&#xD;
             antibodies other than MLN1202.&#xD;
&#xD;
          9. The participant has positive results in urine drug tests at screening.&#xD;
&#xD;
         10. The participant has a history of drug abuse (defined as any illicit drug use) or a&#xD;
             history of alcohol dependence within 2 years prior to the study visit at screening or&#xD;
             is unwilling to agree to abstain from alcohol and drugs throughout the study period.&#xD;
&#xD;
         11. The participant requires any excluded medication or food products listed in the&#xD;
             Excluded Medications and Dietary Products (see section 7.3) during the study period.&#xD;
&#xD;
         12. The participant intends to donate sperm during the study period or period until 12&#xD;
             weeks (84 days) after administration of the study drug.&#xD;
&#xD;
         13. The participant has a history of cancer.&#xD;
&#xD;
         14. The participant has, is suspected of having, or has a history of active tuberculosis&#xD;
             or latent tuberculosis infection.&#xD;
&#xD;
         15. The participant has a positive test result for hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis B virus antibody (hepatitis B surface antibody [HBsAb]/ hepatitis B core&#xD;
             antibody [HBcAb]), hepatitis C virus (HCV) antibody, human immunodeficiency virus&#xD;
             (HIV) antibody/antigen, or serological reactions for syphilis at screening. This does&#xD;
             not include the participant who has a positive test result only for HBsAb due to HBV&#xD;
             vaccination.&#xD;
&#xD;
         16. The participant has used nicotine-containing products (cigarettes, pipes, cigars,&#xD;
             chewing tobacco, nicotine patches, or nicotine gum, etc.) within 4 weeks (28 days)&#xD;
             prior to administration of the study drug.&#xD;
&#xD;
         17. The participant has poor peripheral venous access.&#xD;
&#xD;
         18. The participant has undergone whole blood collection of at least 200 mL within 4 weeks&#xD;
             (28 days) or at least 400 mL within 12 weeks (84 days) prior to administration of the&#xD;
             study drug.&#xD;
&#xD;
         19. The participant has undergone whole blood collection of at least 800 mL in total&#xD;
             within 52 weeks (364 days) prior to administration of the study drug.&#xD;
&#xD;
         20. The participant has undergone blood component collection within 2 weeks (14 days)&#xD;
             prior to administration of the study drug.&#xD;
&#xD;
         21. The participant has any clinically significant electrocardiographic (ECG)&#xD;
             abnormalities at the time of screening or baseline examination.&#xD;
&#xD;
         22. The participant has abnormal laboratory values that suggest a clinically significant&#xD;
             underlying disease, or the participant has the following lab abnormalities at the time&#xD;
             of screening or baseline examination: alanine aminotransferase (ALT) or aspartate&#xD;
             aminotransferase (AST) &gt;1.5 Ã— the upper limits of normal, or differential white blood&#xD;
             count (monocytes) &lt; the lower limit of normal.&#xD;
&#xD;
             The following criteria will be evaluated by laboratory tests at the screening: insulin&#xD;
             (fasting), parathyroid hormone (PTH) (intact).&#xD;
&#xD;
         23. The participant has systolic blood pressure &lt;80 mmHg or diastolic blood pressure &lt;45&#xD;
             mmHg, or systolic blood pressure &gt;160 mmHg or diastolic blood pressure &gt;100 mmHg at&#xD;
             the time of screening, baseline examination or examination prior to administration of&#xD;
             the study drug.&#xD;
&#xD;
         24. The participant is receiving treatment for a wound and is, in the opinion of the&#xD;
             investigator, unsuitable to participate in the study.&#xD;
&#xD;
         25. The participant is scheduled to undergo surgery within 12 weeks (84 days) after&#xD;
             administration of the study drug.&#xD;
&#xD;
         26. In the opinion of the investigator, the participant is unlikely to comply with the&#xD;
             protocol or is unsuitable for any other reasons&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2015</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

